Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillinresistant staphylococcus aureus bacteremia

Virulence

Volumn 4, Issue 8, 2013, Pages

  Seah, Jonathan ^a   Lye, David C ^b,c,d   Ng, Tat Ming ^b   Krishnan, Prabha ^b   Choudhury, Saugata ^b   Teng, Christine B ^b,e  

^a CHANGI GENERAL HOSPITAL   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c NATIONAL CENTRE FOR INFECTIOUS DISEASES   (Singapore)

^d Dept Medicine Endocrinol Diabet   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Combination therapy; Monotherapy; MRSA; Persistent bacteremia; Vancomycin

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; FUSIDIC ACID; GENTAMICIN; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; BACTERIAL ENDOCARDITIS; BONE INFECTION; DISEASE DURATION; EPSILOMETER TEST; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; INFECTIOUS ARTHRITIS; INTRAVASCULAR CATHETER; LENGTH OF STAY; LETTER; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OUTCOME ASSESSMENT; PATHOGEN CLEARANCE; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; BACTEREMIA; DRUG EFFECT; DRUG THERAPY; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MONOTHERAPY; PERSISTENT BACTEREMIA; SINGAPORE; STAPHYLOCOCCUS INFECTION; TEACHING HOSPITAL; THERAPY; TREATMENT OUTCOME; VERY ELDERLY;

COMBINATION THERAPY; MONOTHERAPY; MRSA; PERSISTENT BACTEREMIA; VANCOMYCIN;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG THERAPY; FEMALE; HOSPITALS, TEACHING; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SINGAPORE; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84888377220     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.26909     Document Type: Letter

References (25)

1. Fowler VG Jr., Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, et al.; ICE Investigators. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012-21; PMID:15972563; http://dx.doi.org/10.1001/ jama.293.24.3012
2. Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007; 167:1861-7; PMID:17893307; http://dx.doi.org/10.1001/archinte.167.17.1861
3. Moise PA, Forrest A, Bayer AS, Xiong YQ, Yeaman MR, Sakoulas G. Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes. J Infect Dis 2010; 201:233-40; PMID:20001853; http://dx.doi.org/10.1086/649429
4. Neuner EA, Casabar E, Reichley R, McKinnon PS. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2010; 67:228-33; PMID:20542203; http://dx.doi.org/10.1016/j.diagmicrobio.2010.02.026
5. Fong RK, Low J, Koh TH, Kurup A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 2009; 28:983-7; PMID:19387707; http://dx.doi.org/10.1007/s10096-009-0741-5
6. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199:619-24; PMID:19199552; http://dx.doi.org/10.1086/596629
7. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 2010; 65:1015-8; PMID:20200036; http://dx.doi.org/10.1093/jac/dkq050
8. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-71; PMID:22302374; http://dx.doi.org/10.1093/cid/cir935
9. Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method. BMC Infect Dis 2010; 10:159; PMID:20529302; http://dx.doi.org/10.1186/1471-2334-10-159
10. Wang JT, Wang JL, Fang CT, Chie WC, Lai MS, Lauderdale TL, Weng CM, Chang SC. Risk factors for mortality of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: with investigation of the potential role of community-associated MRSA strains. J Infect 2010; 61:449-57; PMID:20875455; http://dx.doi.org/10.1016/j.jinf.2010.09.029
11. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200; PMID:18171250; http://dx.doi.org/10.1086/524667
12. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315-20; PMID:18591266; http://dx.doi.org/10.1128/AAC.00113-08
13. Lin SH, Liao WH, Lai CC, Liao CH, Tan CK, Wang CY, Huang YT, Hsueh PR. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan. J Antimicrob Chemother 2010; 65:1792-8; PMID:20511366; http://dx.doi.org/10.1093/jac/dkq1886
14. Marchaim D, Kaye KS, Fowler VG, Anderson DJ, Chawla V, Golan Y, Karchmer AW, Carmeli Y. Case-control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2010; 16:747-52; PMID:19723135; http://dx.doi.org/10.1111/j.1469-0691.2009.02934.x
15. Su CT, Hsueh PR, Wu VC, Wang CY, Hu FC, Chen YM, Tsai TJ, Wu KD. Maintenance haemodialysis and delayed administration of appropriate antibiotics increase 30-day mortality among patients with nonhospital-acquired meticillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 2010; 35:511-2; PMID:20181464; http://dx.doi.org/10.1016/j.ijantimicag.2009.12.016
16. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-92; PMID:21217178; http://dx.doi.org/10.1093/cid/cir034
17. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-80; PMID:1929035; http://dx.doi. org/10.7326/0003-4819-115-9-674
18. Tremblay S, Lau TT, Ensom MH. Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence? Ann Pharmacother 2013; 47:1045-54; PMID:23715070; http://dx.doi.org/10.1345/aph.1R726
19. Jang HC, Kim SH, Kim KH, Kim CJ, Lee S, Song KH, Jeon JH, Park WB, Kim HB, Park SW, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009; 49:395-401; PMID:19569970; http://dx.doi.org/10.1086/600295
20. Hussain A, Alleyne S, Jenkins D. A survey of attitudes towards methicillin-resistant Staphylococcus aureus bacteraemias amongst United Kingdom microbiologists. J Antimicrob Chemother 2010; 65:347-9; PMID:20008906; http://dx.doi. org/10.1093/jac/dkp456
21. Thwaites GE; United Kingdom Clinical Infection Research Group (UKCIRG). The management of Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluation. PLoS One 2010; 5:e14170; PMID:21179193; http://dx.doi.org/10.1371/journal.pone.0014170
22. Doern GV, Scott DR, Rashad AL, Kim KS. Evaluation of a direct blood culture disk diffusion antimicrobial susceptibility test. Antimicrob Agents Chemother 1981; 20:696-8; PMID:7325634; http://dx.doi.org/10.1128/AAC.20.5.696
23. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement M100-S20. Wayne, PA, USA: Clinical and Laboratory Standards Institute (CLSI) 2010.
24. Walsh TR, Bolmström A, Qwärnström A, Ho P, Wootton M, Howe R A, MacGowan AP, Diekema D. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39:2439-44; PMID:11427551; http://dx.doi.org/10.1128/JCM.39.7.2439-2444.2001
25. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010; 9:9-14; PMID:20021290; http://dx.doi.org/10.1517/14740330903413514